Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities (PDMRs), and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On October 1, 2015, specific acquisitions of GSK Ordinary shares occurred at a price of 1286.50 pence per share. These transactions resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA). No other material changes to the company's operations or financial position are disclosed in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the disclosure of specific share purchases by insiders.
Important Facts for Investors
- Transaction Date: October 1, 2015.
- Share Price: 1286.50 pence per Ordinary share.
- Transaction Type: Dividend re-investment within an ISA.
- Directors/PDMRs Involved:
- Sir Andrew Witty: 161 shares
- Mr D S Redfern: 24 shares
- Mrs V A Whyte: 21 shares
- Connected Persons Involved:
- Lady C Witty (Connected to Sir Andrew Witty): 41 shares